NDAORALCAPSULE
Approved
Sep 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALBAMYCIN (novobiocin sodium) is an oral antibiotic capsule approved in 1964 for bacterial infections. It is a small-molecule antibiotic with a mechanism targeting bacterial DNA gyrase. The drug treats various gram-positive and gram-negative bacterial infections in patients requiring oral antimicrobial therapy.
LOE Approaching
With LOE approaching and minimal linked job activity, this product likely operates with a small, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALBAMYCIN presents minimal career opportunity with zero linked job openings and an approaching LOE status. Working on this product typically involves defending market share and managing a legacy portfolio rather than driving growth or innovation.
Brand ManagerProduct Manager
Worked on ALBAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.